To gather both qualitative and quantitative information, the primary research process involved interviewing players from both the supply and demand sides. On the supply side, we found healthcare AI developers, medical imaging software providers, and health IT manufacturers, as well as chief technology officers (CTOs), heads of artificial intelligence strategy, managers of regulatory affairs, and sales leaders from these companies. In terms of demand-side sources, we have CMIOs, CDOs, radiology department heads, hospital IT directors, procurement leaders from IDNs, research directors from pharmaceutical companies and academic medical institutes, and others. Through primary research, we were able to confirm the development timelines of AI algorithms, validate the market segmentation across medical imaging and clinical decision support applications, and gain insights into the barriers to clinical adoption, costs of integration with existing EHR systems, and reimbursement pathways for AI-driven diagnostics.
Primary Respondent Breakdown:
By Designation: C-level & Board Level (40%), Director & VP Level (30%), Manager & Technical Leads (30%)
By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)
Global market valuation was derived through revenue mapping and deployment volume analysis. The methodology included:
Identification of 60+ key technology developers and healthcare AI vendors across North America, Europe, Asia-Pacific, and Middle East
Product mapping across machine learning platforms, natural language processing tools, computer vision systems, deep learning algorithms, and robotic process automation
Analysis of reported and modeled annual revenues specific to healthcare AI portfolios, including software licensing, platform subscriptions, and professional services
Coverage of manufacturers and software vendors representing 75-80% of global market share in 2024
Extrapolation using bottom-up (deployment volume × Average Selling Price by clinical application and care setting) and top-down (vendor revenue validation against health system IT spending) approaches to derive segment-specific valuations for medical imaging AI, clinical decision support systems, drug discovery platforms, and administrative workflow automation tools.